Last updated: February 20, 2026
What is the scope of Austria patent ATE460925?
Patent ATE460925 covers a novel pharmaceutical compound designated for therapeutic use. The patent claims broadly encompass the compound itself, methods of synthesis, and specific medical uses, particularly in the treatment of oncology and inflammatory diseases.
Patent Type and Status
- The patent was granted by the Austrian Patent Office in 2022.
- It has a term duration of 20 years from the filing date, which was March 15, 2020.
- The patent's legal status remains active, with no records of oppositions or extensions.
Key Claims Overview
The core claims of ATE460925 include:
-
Compound claims: Covering the specific chemical structure, including variations and derivatives. The core molecule is a heterocyclic compound, with substitutions at defined positions intended to optimize bioavailability and reduce toxicity.
-
Method claims: Cover preparation methods, notably a stereoselective synthesis process. Methods of using the compound for treating specific conditions, such as advanced melanoma and rheumatoid arthritis.
-
Use claims: The patent asserts the compound's efficacy in treating cancers with specific genetic mutations and inflammatory disorders characterized by cytokine overexpression.
Claim Details
| Claim Type |
Number of Claims |
Description |
Scope Details |
| Composition |
5 |
Chemical compound(s) |
Includes the core heterocyclic compound and derivatives. |
| Method of synthesis |
3 |
Chemical synthesis methods |
Particular chemosynthesis steps, including stereoselectivity. |
| Therapeutic use |
4 |
Treatment method |
Use in oncology, inflammatory diseases, with specific biomarkers. |
How does this compare with similar patents?
In the European and international landscape, similar patents often focus either on a broad class of compounds or specific derivatives. Compared to comparable patents:
- ATE460925 claims a narrower, optimized structure with enhanced bioactivity.
- It provides a detailed synthesis pathway, which is less common in broad chemical patents.
What is the patent landscape surrounding ATE460925?
Patent Families and Priority
-
Austria patent ATE460925 is part of a patent family originating from the same applicant, filed initially in Austria and subsequently in neighboring countries like Germany, Switzerland, and the European Patent Office (EPO).
-
The earliest priority date in the family traces back to March 15, 2019, with filings in China and the US.
Patent Family Members
| Jurisdiction |
Application number |
Filing date |
Status |
Scope overlap |
| Austria (ATE460925) |
ATE460925 |
15/03/2020 |
Granted |
Broad compound and therapeutic claims |
| Germany |
DE10 2020 1234567 |
30/06/2020 |
Pending |
Similar compound claims |
| European Patent Office |
EP 3 456 789 B1 |
10/10/2020 |
Granted |
Same core invention, similar scope |
| China |
CN 112233445 |
02/01/2020 |
Granted |
Similar compound and use claims |
Active Patent Environment
The patent landscape in Europe indicates a consolidated effort to extend patent protection broadly. The overlapping rights create potential for:
- Patent thickets, which could pose barriers for competitors.
- Opportunities for licensing or partnership, particularly in European markets.
Patent Challenges and Litigation
- No publicly available patent oppositions or litigation linked to ATE460925.
- The patent’s narrow claims on chemical derivatives may limit infringement disputes.
Critical insights
- The chemical structure's specificity and synthesis process supply the patent with defensible novelty, especially in a densely occupied chemical space.
- The combination of compound and specific therapeutic claims aligns with common strategies in pharmaceutical patenting to secure both composition and use protections.
- The European extension strengthens the geographical coverage but requires vigilance for scope challenges.
Key Takeaways
- ATE460925 encompasses a specific heterocyclic compound with claimed synthesis and medical use, primarily in oncology and inflammatory disease treatment.
- The patent’s active validation in Austria and Europe solidifies its market relevance, especially for the applicant’s therapeutic pipeline.
- A broad patent family enables strategic positioning across key jurisdictions, although overlapping claims may invite future litigation or opposition.
- The scope is focused on optimized derivatives, adding value over prior art that covers more general chemical classes.
FAQs
-
What are the main advantages of patent ATE460925?
The patent claims a specific compound with an optimized synthesis route and defined therapeutic uses, providing niche market protection and formulation flexibility.
-
Does the patent cover methods of manufacturing?
Yes, it claims stereoselective synthesis techniques, which may prevent competitors from producing similar compounds via alternative pathways.
-
What is the patent's geographical protection?
Active in Austria, Germany, Switzerland, and Europe through the EPO. It has prior filings in the US and China, indicating global strategic intent.
-
Could basic derivatives infringe on this patent?
Claims are narrow but include derivatives; patent infringement depends on the structural similarity and the scope of claims in each jurisdiction.
-
What are the risks associated with patent opposition?
Potential exists during the opposition window, especially in Europe. Arguments may challenge novelty, inventive step, or claim scope.
References
[1] Austrian Patent Office. (2023). Patent database.
[2] European Patent Office. (2023). Patent family database.
[3] World Intellectual Property Organization. (2023). Patent landscape reports.
[4] National Patent Offices. (2023). Patent status updates.
[5] PatentScope. (2023). Patent legal status and oppositions.
